• Stronger June quarter revenues, recent sales wins, increase in sales activity
• $2.4m of revenues for the quarter, up 10% from the March quarter
• 18 contract sales wins to new and existing clients totalling $3.5m in revenues

Hydrix Limited (ASX: HYD) released its Appendix 4C for the quarter ended 30 June 2025 (4QFY25) and provided a market update. The key highlights include:Hydrix Services:- Stronger June quarter revenues, recent sales wins, and increase in sales activity- $2.4m of revenues for the quarter, up 10% from the March quarter, primarily in cardiac and medtech products, with emerging growth from defence clients- 18 contract sales wins to new and existing clients totalling $3.5m in revenues- 20 active clients where paid work is currently being undertaken, providing a $40.0m potential future project revenue baseOther Group Updates:- Hydrix Medical is progressing sales opportunities of its remote cardiac monitoring software- $0.3m cash on hand plus a $2.0m Letter of Comfort from a major shareholder provided in August 2024 (of which $0.75m has been drawn down)- $0.76m operating loss, a 45% improvement to the $1.4m operating loss in the prior corresponding periodHydrix Executive Chairman, Gavin Coote, commented that the company is encouraged by the increased sales activity and a range of emerging growth opportunities. The Board sees several opportunities to grow the business and unlock shareholder value, committing working capital to support the company's forward progress.

The company is well placed to build further revenue momentum in the December half, with recent sales outcomes and a range of emerging growth opportunities.